{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Onxyf8LDA","lastupdate":"2022-12-07T00:00:00.000Z","update_date":"2022-12-07T00:00:00.000Z","lastModified":"Jun 18, 2025","active":1,"confidence_score":89,"confidence_score_reason":"video or image, markets, not claimed","urlname":"kamari-pharma","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$oz90EKLeKCtUu7Af0WmfdyhdWiFbO82jAXi1UpuwvyfsbJn5t7zAu7","name":"Kamari Pharma","oneliner":"Small Molecule Inhibitors of TRPV3","registrar":"515880847","website":"https://kamaripharma.com/","careerspage":"","founded_month":10,"founded_year":2018,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/83017944","instagram":""},"social":["https://www.linkedin.com/company/83017944"],"flattenedsociallinks":"https://www.linkedin.com/company/83017944","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"1-10","employees_exact":9,"patent":1,"raised":31000000,"stage":"A","public_stage":"A","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Kamari.Pharma","Kamari-Pharma","Camari Pharma","KamariPharma"],"about":"Kamari Pharma is a biopharmaceutical company aiming to develop and commercialize proprietary small molecule inhibitors of TRPV3, a cation channel expressed primary in keratinocytes, for the treatment of dermatological conditions with unmet need. \r\nTRPV3 has been extensively evaluated as a target for drug development, identified as the cause of Olmsted syndrome in humans, and shows involvement in various skin disorders including keratoderma, atopic dermatitis, psoriasis, rosacea, and post-burn pruritus.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+972 8 853-2774","country":null,"address":{"israeli":[{"id":"e88d2274-4a3a-4138-afc6-241a0a4e3ed6","city":"Ness Ziona","type":null,"address":"Pinhas Sapir Street 3, Ness Ziona, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"Y9JcstBj3ygTehQ2jR8nSsSdaM3xZEGXgwxPOqiuSKsVKkzBzPeUtS","date":"Jun 2, 2025","link":"https://www.globenewswire.com/news-release/2025/06/03/3092474/0/en/Kamari-Pharma-Announces-Closing-of-23-Million-Financing-to-Advance-its-First-In-Class-Oral-TRPV3-Inhibitor-for-Rare-Genetic-Skin-Diseases.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"investment","round":"Series A","company":"Kamari Pharma","layoffs":null,"summary":"Kamari Pharma, a clinical-stage biotechnology company, has secured $23 million in Series A financing co-led by BRM Group and Pontifax. The funds will be used to advance Kamaris lead program, KM023, an oral TRPV3 inhibitor, into clinical development for treating rare genetic skin diseases such as Olmsted syndrome, severe keratoderma, and ichthyosis. The company plans to commence a Phase 1b clinical trial for Olmsted syndrome by the end of 2025. Kamaris approach in the rare dermatology space is distinguished by its focus on TRPV3 inhibition, and the investment will accelerate the development of KM023.","partners":null,"customers":null,"eventType":null,"investors":["BRM Group","Pontifax"],"confidence":9,"key_topics":["Financing","Clinical Trials","Rare Diseases","TRPV3 Inhibitor","Dermatology"],"date_of_event":"June 03, 2025","product_stage":"clinical trial","investment_date":"June 03, 2025","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$23 million","structured_issues":["Investment","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Investment  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fsyw5f5973Ap0DklUSxf20FwMX5e54qjEj3VUj8MGhxjYLIh0AkLPO","news_summary":"Kamari Pharma Announces Closing of $23 Million Financing to Advance its First-In-Class Oral TRPV3 Inhibitor for Rare Genetic Skin Diseases","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"qd9vsr2e8qacMq8TDll1uybNVPh6tmRTyisuyps6Ji8RsxGEIkti9H","date":"Sep 18, 2022","link":"https://forbes.co.il/e/kamari-pharma-raises-8-million-from-gibf2/","source":"forbes.co.il","visible":1,"analysis":{"tags":"investment","company":"Kamari Pharma","layoffs":null,"summary":"Kamari Pharma, a clinical stage company developing drugs for dermatological diseases, has announced an $8 million investment from Chinese fund GIBF2. The company, founded by Pontifax and Arkin Bioholdings, has received a total investment of $16 million. Kamari develops drugs based on proprietary small molecules for the treatment of various dermatological diseases. The investment will allow Kamari to continue promoting its clinical programs and expand its clinical trials by collaborating with leading hospitals in China. GIBF2, a Chinese investment fund, focuses on Western biotechnology companies in phase 2-3 of clinical trials. The fund aims to develop innovative activity in China and build value in the Chinese market.","partners":null,"customers":null,"investors":"GIBF2","confidence":9,"key_topics":["Kamari Pharma","investment","clinical trials","dermatological diseases","GIBF2"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$8 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UB3GM6bHlmNCvAdZMtQ0lqrpkmasCUp3rslOzxRDGvzqAgPC633g8G","news_summary":"Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund - Forbes Israel","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":2,"techcommunityinvolvement":null,"mediagallery":[],"tags":["biopharmaceutical","drug-development","dermatology","pharma-companies","skin","rare-diseases","pharmaceuticals"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"R&D","products":[],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":4,"lastfunding":"$23M","totalrounds":3,"fundingstage":"A","totalfunding":"$31M","publicinvestors":4,"lastpublicfunding":23000000,"totalpublicrounds":3,"totalpublicfunding":31000000},"team":[{"name":"David  Aviezer ","email":"","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAkNrIh6YIDA","bounced":false,"claimed":0,"founder":0,"urlname":"david-aviezer-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICQqr7D8QsM","position":" Executive Chairman","last_name":"Aviezer ","claimtoken":"WLMdww2RRVtvONeDd6PWSD7Og84MjEPSakwn1VzJMnm7yC4JN1MIPL","first_name":"David ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/david-aviezer-986a1821/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-12-07 16:48:35.000000","initials":"DA","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Liora   Braiman-Wiksman ","email":"liora@kamaripharma.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAkJqbqZoLDA","bounced":false,"claimed":0,"founder":0,"urlname":"liora-braiman-wiksman","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICQmrn61AoM","position":" Chief Scientific Officer","last_name":" Braiman-Wiksman ","claimtoken":"B9ccWGZOdJSNhfRnDVhNit6rl7z0LyLOpo8XjEC2I9THAQ4gXs6JeR","first_name":"Liora ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/liora-braiman-wiksman-a081a710/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-12-07 16:48:33.000000","initials":"L ","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Dayana  Michel","email":"","phone":"","gender":"Female","userid":"Uk4ngqYCoMaqc9SPix3aNhLPP1aW0ut5wrIT2wPC02B9CVJxgdXLzq","bounced":false,"claimed":null,"founder":0,"urlname":"dayana-michel","visible":1,"memberid":"RSs6sYFlEDQtGXDkX0JFdq5CV7ClOTg9KOi94zBviUdZRHI8wgBZbX","position":"VP Medical","last_name":"Michel","claimtoken":"OL0SeXvAWfNsJy0NmJLeuiq4lJa2G6VljZx9tTdbbEb5YdiQkJqXOC","first_name":"Dayana ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/dayana-michel-m-d-a6646823/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-12-07 16:50:55.000000","initials":"DM","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Asaf Yarkoni","email":"asaf@kamaripharma.com","phone":"","gender":"male","userid":"Y1PPxbtkKV4DFTwxmvhqYiMppPcxu6p2JgCkQV6GsHVSJxcmBRGPjV","bounced":false,"claimed":1,"founder":null,"urlname":"asaf-yarkoni","visible":0,"memberid":"64RtxCaZC1D8AOPVW6lQ4O00elJl6aRGVYFxrhUpkwQQ8k3vcoHTnn","position":"","last_name":"Yarkoni","claimtoken":null,"first_name":"Asaf","picturekey":null,"claimeddate":"2022-12-08","linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"AY","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='<style>\n    .visibility-tooltip-container {\n        display: flex;\n        column-gap: 0.8rem;\n        padding: 0.8rem 1rem;\n        align-items: center;\n    } \n\n    .visibility-tooltip-container text {\n        font-size: 1.4rem;\n        text-transform: capitalize;\n        font-weight: 500;\n    }\n</style>\n\n<div class=\"visibility-tooltip-container\">\n    <img height=\"20\" width=\"20\" style=\"display: flex\" src=\"/assets/private-visibility.svg\"/>\n    <img height=\"20\" width=\"20\" style=\"display: none\" src=\"/assets/internal-visibility.svg\"/>\n    <text>private</text>\n</div>'"},{"name":" ","email":"asaf@kamaripharma.com","phone":"","gender":null,"userid":"Y1PPxbtkKV4DFTwxmvhqYiMppPcxu6p2JgCkQV6GsHVSJxcmBRGPjV","bounced":false,"claimed":1,"founder":null,"urlname":"asaf-yarkoni","visible":0,"memberid":"IrluHiEaKSG3pteyChQwvqxXDDbMj2wyTMr9MD8uY5gztUbTPs7O2l","position":null,"last_name":"","claimtoken":null,"first_name":"","picturekey":null,"claimeddate":"2022-12-08","linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"","pictureurl":"/assets/empty-state.svg","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='<style>\n    .visibility-tooltip-container {\n        display: flex;\n        column-gap: 0.8rem;\n        padding: 0.8rem 1rem;\n        align-items: center;\n    } \n\n    .visibility-tooltip-container text {\n        font-size: 1.4rem;\n        text-transform: capitalize;\n        font-weight: 500;\n    }\n</style>\n\n<div class=\"visibility-tooltip-container\">\n    <img height=\"20\" width=\"20\" style=\"display: flex\" src=\"/assets/private-visibility.svg\"/>\n    <img height=\"20\" width=\"20\" style=\"display: none\" src=\"/assets/internal-visibility.svg\"/>\n    <text>private</text>\n</div>'"}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNqyo8cLDA","fullname":"Yotam Maman"},"biverifydate":"2020-08-19T00:00:00.000Z","crunchbaseid":"","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Yotam Maman","creator_email":"yotamm1988@gmail.com","createdate":"2020-08-19T00:00:00.000Z","biverification":"Yotam Maman","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"fyioTiVTvD2G0wTPX2SeXwdPieKY9lieo1bfhM0iS7evvzohWTfzY3","date":"Jun 2025","amount":"$23M","source":"https://www.globenewswire.com/news-release/2025/06/03/3092474/0/en/Kamari-Pharma-Announces-Closing-of-23-Million-Financing-to-Advance-its-First-In-Class-Oral-TRPV3-Inhibitor-for-Rare-Genetic-Skin-Diseases.html","eventtype":"FundingRoundEvent","investment":[{"name":"Pontifax","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"NvsAElnR9uRSufXiZVMpTCymaZ0pHIJ5wyGVwpaXe5FHuCrLCGSReC","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead&nbsp;","followupcaption":"Follow on&nbsp;"},{"name":"BRM Group","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/brm-group","logokey":"$K4vzA5SahlHA7RuyaB3JP0K6of1igSvdSyRPckpQ0hIgFIm4BzSJLD","tagline":null,"urlname":"/investor_page/brm-group","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP6j-5ULDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"mXa3grRei5RCErWrraggEdsry7z5fFD19NNP7uuth9mbQmlVb5mlmu","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$K4vzA5SahlHA7RuyaB3JP0K6of1igSvdSyRPckpQ0hIgFIm4BzSJLD","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead&nbsp;","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":23000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"sAoC278EVeZJ4Mf5dTLIQ7Nh7DwoVNSszaHFSVlpiSxCa54yQVNvfF","date":"Sep 2022","amount":"$8M","source":"https://forbes.co.il/e/kamari-pharma-raises-8-million-from-gibf2/","eventtype":"FundingRoundEvent","investment":[{"name":"Guangzhou Sino-Israel Biotech Investment Fund (GIBF)","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/guangzhou-sino-israel-biotech-investment-fund-gibf","logokey":"$EhT54op1KN0bFQNfuNUIQuiaUEJvmdfmQuYVDy8ZGOHTKVos9xOEZg","tagline":null,"urlname":"/investor_page/guangzhou-sino-israel-biotech-investment-fund-gibf","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Nf6pOwIDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"TDgr1I5aUZfSD4a9iMijBveL4q7RFzr7hNaDsahGDyqJYCt55EkqXn","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$EhT54op1KN0bFQNfuNUIQuiaUEJvmdfmQuYVDy8ZGOHTKVos9xOEZg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":8000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODp8fiWCAw","date":"Jan 2020","amount":"Undisclosed","source":"https://www.pontifax.com/wp-content/uploads/2019/12/Kamari-One-pager-2019.pdf, Rasham Ha-havarot","eventtype":"FundingRoundEvent","investment":[{"name":"Arkin Bio","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/arkin-bio","logokey":"","tagline":null,"urlname":"/investor_page/arkin-bio","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoJWcgNEJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"2e8c322e-9299-49d3-8476-772200cec79d","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"ee66dc6d-0500-46d6-8ea4-21d0a67e07bb","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"10/2018","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Kamari Pharma","logourl":"https://storage.googleapis.com/clean-finder-353810/$oz90EKLeKCtUu7Af0WmfdyhdWiFbO82jAXi1UpuwvyfsbJn5t7zAu7","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$oz90EKLeKCtUu7Af0WmfdyhdWiFbO82jAXi1UpuwvyfsbJn5t7zAu7","seoabout":"Kamari Pharma is a biopharmaceutical company aiming to develop and commercialize proprietary small molecule inhibitors of TRPV3, a cation channel expressed...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":5,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Molecules","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Molecules"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Molecules"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"fyioTiVTvD2G0wTPX2SeXwdPieKY9lieo1bfhM0iS7evvzohWTfzY3","date":"Jun 2025","amount":"$23M","source":"https://www.globenewswire.com/news-release/2025/06/03/3092474/0/en/Kamari-Pharma-Announces-Closing-of-23-Million-Financing-to-Advance-its-First-In-Class-Oral-TRPV3-Inhibitor-for-Rare-Genetic-Skin-Diseases.html","eventtype":"FundingRoundEvent","investment":[{"name":"Pontifax","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"NvsAElnR9uRSufXiZVMpTCymaZ0pHIJ5wyGVwpaXe5FHuCrLCGSReC","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead&nbsp;","followupcaption":"Follow on&nbsp;"},{"name":"BRM Group","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/brm-group","logokey":"$K4vzA5SahlHA7RuyaB3JP0K6of1igSvdSyRPckpQ0hIgFIm4BzSJLD","tagline":null,"urlname":"/investor_page/brm-group","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP6j-5ULDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"mXa3grRei5RCErWrraggEdsry7z5fFD19NNP7uuth9mbQmlVb5mlmu","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$K4vzA5SahlHA7RuyaB3JP0K6of1igSvdSyRPckpQ0hIgFIm4BzSJLD","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead&nbsp;","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":23000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"sAoC278EVeZJ4Mf5dTLIQ7Nh7DwoVNSszaHFSVlpiSxCa54yQVNvfF","date":"Sep 2022","amount":"$8M","source":"https://forbes.co.il/e/kamari-pharma-raises-8-million-from-gibf2/","eventtype":"FundingRoundEvent","investment":[{"name":"Guangzhou Sino-Israel Biotech Investment Fund (GIBF)","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/guangzhou-sino-israel-biotech-investment-fund-gibf","logokey":"$EhT54op1KN0bFQNfuNUIQuiaUEJvmdfmQuYVDy8ZGOHTKVos9xOEZg","tagline":null,"urlname":"/investor_page/guangzhou-sino-israel-biotech-investment-fund-gibf","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Nf6pOwIDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"TDgr1I5aUZfSD4a9iMijBveL4q7RFzr7hNaDsahGDyqJYCt55EkqXn","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$EhT54op1KN0bFQNfuNUIQuiaUEJvmdfmQuYVDy8ZGOHTKVos9xOEZg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":8000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODp8fiWCAw","date":"Jan 2020","amount":"Undisclosed","source":"https://www.pontifax.com/wp-content/uploads/2019/12/Kamari-One-pager-2019.pdf, Rasham Ha-havarot","eventtype":"FundingRoundEvent","investment":[{"name":"Arkin Bio","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/arkin-bio","logokey":"","tagline":null,"urlname":"/investor_page/arkin-bio","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoJWcgNEJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"2e8c322e-9299-49d3-8476-772200cec79d","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"ee66dc6d-0500-46d6-8ea4-21d0a67e07bb","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}